Structure Therapeutics (NASDAQ:GPCR – Get Free Report)‘s stock had its “market outperform” rating restated by research analysts at Citizens Jmp in a report released on Wednesday, Benzinga reports. They currently have a $110.00 target price on the stock. Citizens Jmp’s price objective would indicate a potential upside of 172.41% from the stock’s current price.
Several other analysts have also recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Friday, July 17th. Wall Street Zen raised Structure Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, August 17th. Canaccord Genuity Group set a $111.00 price target on Structure Therapeutics in a research note on Friday, August 7th. Citigroup restated a “market outperform” rating on shares of Structure Therapeutics in a report on Friday, August 7th. Finally, HC Wainwright reiterated a “buy” rating on shares of Structure Therapeutics in a report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $110.91.
View Our Latest Analysis on GPCR
Structure Therapeutics Price Performance
Structure Therapeutics (NASDAQ:GPCR – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). As a group, equities research analysts anticipate that Structure Therapeutics will post -1.87 EPS for the current year.
Hedge Funds Weigh In On Structure Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the stock. Wellington Management Group LLP lifted its position in shares of Structure Therapeutics by 1.6% during the second quarter. Wellington Management Group LLP now owns 7,379,433 shares of the company’s stock worth $396,054,000 after purchasing an additional 119,146 shares in the last quarter. Avoro Capital Advisors LLC increased its stake in Structure Therapeutics by 21.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 6,555,555 shares of the company’s stock worth $455,939,000 after buying an additional 1,150,000 shares during the period. Janus Henderson Group PLC lifted its holdings in Structure Therapeutics by 5.2% in the 1st quarter. Janus Henderson Group PLC now owns 5,354,981 shares of the company’s stock worth $258,260,000 after buying an additional 264,833 shares in the last quarter. BVF Inc. IL boosted its position in Structure Therapeutics by 8.6% in the 4th quarter. BVF Inc. IL now owns 3,479,022 shares of the company’s stock valued at $241,966,000 after buying an additional 275,105 shares during the last quarter. Finally, Morgan Stanley grew its stake in shares of Structure Therapeutics by 261.4% during the fourth quarter. Morgan Stanley now owns 2,087,834 shares of the company’s stock valued at $145,209,000 after acquiring an additional 1,510,093 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.
Structure Therapeutics Company Profile
Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.
The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.
Featured Stories
- Five stocks we like better than Structure Therapeutics
- Intel’s ASML Milestone Gives Investors a New Reason to Revisit the Stock
- Defense, Solar, and Refining Stocks Split as the Iran Conflict Raises Energy Risk
- 3 Stocks to Buy and Hold for Higher Interest Rates
- Lululemon’s Problems May Not Be a Warning for Every Athleticwear Stock
Receive News & Ratings for Structure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Structure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
